These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 8318688)

  • 21. Subcutaneous versus intravenous recombinant human erythropoietin administration in hemodialysis patients.
    Boran M; Dalva I; Yazicioğlu A; Cetin S
    Nephron; 1993; 63(1):113-4. PubMed ID: 8446239
    [No Abstract]   [Full Text] [Related]  

  • 22. [Ergometric results of r-erythropoietin treatment of hemodialysis patients].
    Hortian B; Schmidt R; Wüstenberg PW; Dörp E; Schumann L; Winkler R; Klinkmann H
    Z Gesamte Inn Med; 1990 May; 45(10):274-7. PubMed ID: 2392856
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Erythropoietin treatment in Piedmont and Valle d'Aosta].
    Imarisio P; Biamino E; Bongiorno P; Caligaris F; Demicheli G; Montalcini G; Arnaud A
    Minerva Urol Nefrol; 1991; 43(3):143-5. PubMed ID: 1817336
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Differences in intravenous and subcutaneous application of recombinant human erythropoietin: a multicenter trial.
    Schaller R; Sperschneider H; Thieler H; Dutz W; Hans S; Voigt D; Marx M; Engelmann J; Schöter KH; Scigalla P
    Artif Organs; 1994 Aug; 18(8):552-8. PubMed ID: 7993190
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of low dose recombinant human omega erythropoietin (rHuEPO) on anaemia in patients on hemodialysis.
    Acharya VN; Sinha DK; Almeida AF; Pathare AV
    J Assoc Physicians India; 1995 Aug; 43(8):539-42. PubMed ID: 8772973
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Statement on the clinical use of recombinant erythropoietin in anemia of end-stage renal disease. Ad Hoc Committee for the National Kidney Foundation.
    Am J Kidney Dis; 1989 Sep; 14(3):163-9. PubMed ID: 2672796
    [No Abstract]   [Full Text] [Related]  

  • 27. Weekly subcutaneous recombinant human erythropoietin corrects anemia of progressive renal failure.
    Zappacosta AR; Perras ST; Bell A
    Am J Med; 1991 Sep; 91(3):229-32. PubMed ID: 1892142
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Erythropoietin in continuous ambulatory peritoneal dialysis: experience with subcutaneous administration.
    Eisele G; Bailie GR; Clement C; Wong E
    Perit Dial Int; 1992; 12(1):34-6. PubMed ID: 1543777
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparative effects of erythropoietin with oral iron in peritoneal dialysis and hemodialysis patients.
    Raja R; Bloom E; Johnson R
    Adv Perit Dial; 1993; 9():177-80. PubMed ID: 8105918
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety and efficacy of low-dose subcutaneous erythropoietin in hemodialysis patients.
    Parker KP; Mitch WE; Stivelman JC; Macon EJ; Bailey JL; Sands JM
    J Am Soc Nephrol; 1997 Feb; 8(2):288-93. PubMed ID: 9048348
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Human recombinant erythropoietin (rH-EPO) in chronic hemodialysis patients].
    Jalil R; Vaccarezza A; Jara A; Lira P; Vial S; Serrano V
    Rev Med Chil; 1990 Jun; 118(6):629-34. PubMed ID: 1775783
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of dialysis factors and route of administration on response of hemodialysis patients to recombinant human erythropoietin.
    Besarab A; Besarab FM; Miller D
    ASAIO Trans; 1991; 37(3):M181-2. PubMed ID: 1751101
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Understanding epoetin use: databases or clinical trials?
    Roger SD
    Nephrology (Carlton); 2007 Apr; 12(2):118-9. PubMed ID: 17371331
    [No Abstract]   [Full Text] [Related]  

  • 34. [The use of erythropoietin beta, two to three times per week, once per week and once every other week: meta-analysis of two clinical trials].
    Pljesa S
    Med Pregl; 2007; 60(3-4):123-7. PubMed ID: 17853722
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Effect of human recombinant erythropoietin therapy on protein metabolism of patients with terminal renal failure on hemodialysis].
    Scigalla P; Fischer C; Park W; Becker H; Schiller R; Paust H; Brösicke H; Kessel M
    Beitr Infusionsther; 1990; 25():430-8. PubMed ID: 1690065
    [No Abstract]   [Full Text] [Related]  

  • 36. Clinical efficacy of recombinant human erythropoietin in the treatment of anemia in hemodialysis patients: influence of dosing regimen, iron status, and serum aluminum.
    Tsai JC; Lai YH; Tsai ZY; Chien LJ; Tsai JH
    Gaoxiong Yi Xue Ke Xue Za Zhi; 1991 Mar; 7(3):126-35. PubMed ID: 1865507
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment of anaemia in dialysis patients with unit dosing of darbepoetin alfa at a reduced dose frequency relative to recombinant human erythropoietin (rHuEpo).
    Locatelli F; Canaud B; Giacardy F; Martin-Malo A; Baker N; Wilson J
    Nephrol Dial Transplant; 2003 Feb; 18(2):362-9. PubMed ID: 12543893
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Efficacy and safety of long-term erythropoietin therapy in chronic hemodialysis patients with renal anemia].
    Ohkubo M; Ishimitsu T; Kawaguchi T; Abe M; Yagi S
    Nihon Jinzo Gakkai Shi; 1993 Feb; 35(2):171-7. PubMed ID: 8315880
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of subcutaneous and intravenous recombinant human erythropoietin for anemia in hemodialysis patients with significant comorbid disease.
    Muirhead N; Churchill DN; Goldstein M; Nadler SP; Posen G; Wong C; Slaughter D; Laplante P
    Am J Nephrol; 1992; 12(5):303-10. PubMed ID: 1488998
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Human recombinant erythropoietin in the treatment of anemia in patients on long-term hemodialysis].
    Boratyńska M; Szewczyk Z; Szepietowski T; Czyz W; Cybulski K; Bogucki J; Szczepański J
    Przegl Lek; 1990; 47(11):741-5. PubMed ID: 2098840
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.